Last reviewed · How we verify
Zometa
At a glance
| Generic name | Zometa |
|---|---|
| Also known as | Zoledronic acid, zoledronic acid, lupron, zolodex, zolodronic acid |
| Sponsor | University of Arkansas |
| Target | Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Bone Metastases of Solid Tumors
- Glucocorticoid Induced Osteoporosis
- Humoral hypercalcemia of malignancy
- Hypogonadal Osteoporosis in Males
- Osteitis deformans
- Osteolytic Lesions of Multiple Myeloma
- Osteoporosis
- Postmenopausal osteoporosis
- Prevention of Glucocorticoid-Induced Osteoporosis
Common side effects
- Fever
- Nausea
- Constipation
- Anemia
- Dyspnea
- Hypocalcemia
- Hypophosphatemia
- Hypomagnesemia
- Pyrexia
- Fatigue
- Bone pain
- Arthralgias
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (PHASE1, PHASE2)
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors (PHASE1, PHASE2)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Zoledronate In the Prevention of Paget's Disease: Long Term Extension
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Contribution of Bone to Urine Citrate
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zometa CI brief — competitive landscape report
- Zometa updates RSS · CI watch RSS
- University of Arkansas portfolio CI